

10/524046

DT01 PCT/PT 07 FEB 2005  
Docket No. 4439-4030

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Seiji Ozawa et al

Group Art Unit: tbaa

Serial No.: tba

Examiner: tba

Filed: February 7, 2005 (herewith)

For: INHIBITION OF PROLIFERATION AND INFILTRATION OF BRAIN TUMOR  
CELLS CAUSED BY EXPRESSION OF AMPA-TYPE GLUTAMATE  
RECEPTOR SUBUNIT

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R.

§§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.

107524046

DT01 Rec'd PCT/PTO 07 FEB 2005

4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:

- ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or
- ☒ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
- ☐ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
- ☐ 37 C.F.R. §1.97(b)(4), before the mailing date of a first office action after the filing of an RCE under §1.114.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500., Order No. 4439-4030. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: February 7, 2005

By: \_\_\_\_\_

*Michael A. Willis*  
Kenneth H. Sonnenfeld / Michael A. Willis  
Reg. No. 33,285 / Reg. No. 53,913

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.  
3 World Financial Center  
New York, NY 10281-2101  
(212) 415-8700 Telephone  
(212) 415-8701 Facsimile

DUPLICATE

Docket No. 4439-4030

Serial No. <sup>tha</sup>

107524046

DT01 Rec'd PCT/PT 07 FEB 2005

4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:


- ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or
- ☒ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
- ☐ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
- ☐ 37 C.F.R. §1.97(b)(4), before the mailing date of a first office action after the filing of an RCE under §1.114.

- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500., Order No. 4439-4030. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: February 7, 2005

By: \_\_\_\_\_

  
Kenneth H. Sonnenfeld / Michael A. Willis  
Reg. No. 33,285 / Reg. No. 53,913

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.  
3 World Financial Center  
New York, NY 10281-2101  
(212) 415-8700 Telephone  
(212) 415-8701 Facsimile

<b>FORM PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b>				Attorney Docket: 4439-4030		Serial No.: tba <b>10/524046</b>	
				Applicant: Seiji Ozawa et al			
				Filing Date: February 7, 2005 (herewith)		Group Art Unit: tba	

U.S. PATENT DOCUMENTS							
Examiner Initial		Patent Number	Issue Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS							
Examiner Initial		Patent Number	Publication Date	Country	Class	Sub-Class	Translation
							<input type="checkbox"/> Yes <input type="checkbox"/> No
							<input type="checkbox"/> Yes <input type="checkbox"/> No
							<input type="checkbox"/> Yes <input type="checkbox"/> No
							<input type="checkbox"/> Yes <input type="checkbox"/> No
							<input type="checkbox"/> Yes <input type="checkbox"/> No

OTHER DOCUMENTS (Including Author, Title, Date, etc.)		
		Rzeski, W. et al., Glutamate antagonists limit tumor growth, Proc. Natl. Acad. Sci., vol. 98, issue 11, pages 6372-7, May 22, 2001
		Mass, S. et al., Underediting of glutamate receptor GluR-B mRNA in malignant gliomas, Proc. Natl. Acad. Sci., vol. 98, issue 25, pages 14687-92, December 4, 2001
		Ishiuchi, S. et al., Extension of glial processes by activation of Ca <sup>2+</sup> -permeable AMPA receptor channels, Neuroreport, vol. 12, issue 4, pages 745-8, March 26, 2001

Examiner	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	